Search Results
Dec 08, 2025, 09:00 ET From Content Complexity to Connected Retailing: 7 Transformations Redefining Travel in 2026 -- Led by the Rise of Agentic AI
retail strategy. In 2026, travel providers will embrace payments as an integral product.The shift is already underway. Payments are no longer a post-booking pain point, but one of the industry's most powerful enablers. Effective payment hubs are emerging as connected systems that simplify operations,
More news about: Sabre Corporation
Dec 08, 2025, 08:54 ET SSA Petitions U.S. Regulators to Align GENIUS Act Implementation Issue USDT High-Risk Guidance, and Establish On-chain Node KYC
Black Markets—as the strategic banner for international alignment and domestic enforcement. CIFB is to digital finance what counterterrorism was to post-9/11 geopolitics: a moral, strategic, and operational doctrine. This is not about suppressing innovation—it is about removing the underworld reefs on
More news about: Stablecoin Standards Authority
Dec 08, 2025, 08:37 ET A New Chapter in Hormone Health: Dr. Rachel Fishman Oiknine Brings MDVIP's Personalized Model to St. Louis
for specialized care has never been greater. An estimated 75 million women in the United States are currently in perimenopause, menopause, or post-menopause, yet many do not receive the timely diagnosis or symptom support they need. Additionally, the American Association of Clinical Endocrinology estimates
More news about: MDVIP
Dec 08, 2025, 08:36 ET Berger Montague PC Investigating Claims on Behalf of StubHub Holdings, Inc. (NYSE: STUB) Investors After Class Action Filing
complex civil litigation, class actions, and mass torts in federal and state courts throughout the United States. With more than $2.4 billion in 2025 post-trial judgments alone, the Firm is a leader in the fields of complex litigation, antitrust, consumer protection, defective products, environmental law,
More news about: Berger Montague
Dec 08, 2025, 08:36 ET SubjectWell Unveils New Science-Driven Framework to Transform Protocol Design, Recruitment, Engagement, and Retention
intelligence and efficiency for sponsors, CROs, sites, and site networks. From protocol development through recruitment, enrollment, retention, and post-trial real-world evidence studies, SubjectWell supports the entire clinical lifecycle. To learn more, visit
More news about: SubjectWell
Dec 08, 2025, 08:34 ET Agiloft Launches Enterprise-Grade Obligation Management, Pioneering the AI-Native Era of Contract Lifecycle Management
Enterprises gain real-time visibility and control over post-signature obligations, helping reduce risk, enforce compliance, and accelerate business outcomes, turning contract data into operational intelligenceREDWOOD CITY, Calif., Dec.
More news about: Agiloft
Dec 08, 2025, 08:30 ET Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting
indication and labeling; the commercial launch and future sales of Aramchol and any future product candidates; our ability to comply with all applicable post-market regulatory requirements for Aramchol, or any other product candidate in the countries in which we seek to market the product; our ability to
More news about: Galmed Pharmaceuticals Ltd.
Dec 08, 2025, 08:00 ET Autocrypt Announces Product Release of Post-Quantum PKI Product, Pioneering PQC-enabled Solutions for Automotive OEMs
announced on December 8, 2025, the launch of "AutoCrypt PKI-Vehicles," a new next-generation Public Key Infrastructure (PKI) solution supporting ML-DSA, a post-quantum digital signature algorithm. With its announcement, Autocrypt is among the early leaders to commercialize ML-DSA-enabled PKI that can be applied
More news about: AUTOCRYPT
Dec 08, 2025, 08:00 ET Autocrypt Announces Product Release of Post-Quantum PKI Product, Pioneering PQC-enabled Solutions for Automotive OEMs
announced on December 8, 2025, the launch of "AutoCrypt PKI-Vehicles," a new next-generation Public Key Infrastructure (PKI) solution supporting ML-DSA, a post-quantum digital signature algorithm. With its announcement, Autocrypt is among the early leaders to commercialize ML-DSA-enabled PKI that can be applied
More news about: AUTOCRYPT
Dec 08, 2025, 08:00 ET Pierre Fabre Pharmaceuticals Announces Updated Phase 3 Tabelecleucel Data at American Society of Hematology Meeting in Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)
ethics and climate transition at the heart of our action.Pierre Fabre Pharmaceuticals has therapies in development for Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD), NRAS-mutant melanoma, non-small cell lung cancer with mutation or amplification of MET, and X-Linked
More news about: Pierre Fabre Pharmaceuticals
Dec 08, 2025, 08:00 ET IBM to Acquire Confluent to Create Smart Data Platform for Enterprise Generative AI
applications and AI agents Transaction expected to be accretive to adjusted EBITDA within the first full year, and free cash flow in year two, post closeARMONK, N.Y. and MOUNTAIN VIEW, Calif., Dec. 8, 2025
More news about: IBM
Dec 08, 2025, 07:30 ET Scowtt Raises $12M Series A to Transform Performance Marketing with AI-Powered Advertising Platform
system where businesses automate marketing performance using CRM intelligence while also deploying Agentic AI to identify and complete sales.In a post-cookie advertising landscape where traditional "look-alike" targeting has become less effective, Scowtt's AI-driven algorithms analyze customers' proprietary
More news about: Scowtt Inc
Dec 08, 2025, 07:30 ET Contango ORE and Dolly Varden Silver Announce Merger to Create a New North American High-Grade, Mid-Tier Silver & Gold Producer and Developer
Contango and Dolly Varden's intent, or the beliefs or current expectations of the officers and directors of Contango and Dolly Varden for MergeCo post-closing. Actual results and outcomes of the proposed Transaction may vary materially from the amounts set out in any Forward-looking Information. As well,
More news about: Contango Ore
Dec 08, 2025, 07:00 ET UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduced countable motor seizure frequency in CDKL5 deficiency disorder
treatment, patients must undergo an echocardiogram to evaluate for VHD and PAH. Echocardiograms should be repeated every 6 months, and once 3-6 months post treatment with FINTEPLA.The prescriber must consider the benefits versus the risks of initiating or continuing treatment with FINTEPLA if any
More news about: UCB
Dec 08, 2025, 05:40 ET Un'offerta da cogliere al volo: DJI ROMO scontato quasi del 40% per Natale
.Termini di assistenza post-venditaL'acquisto dell'Extended Protection Plan fornisce un'ulteriore garanzia di un anno dopo la scadenza del periodo di garanzia ufficiale del
More news about: DJI
Dec 08, 2025, 02:00 ET DCK Becomes Exclusive Power-Tool Partner of CFMOTO Thunder Racing Team
capabilities.As part of the partnership, DCK will supply the team with a full suite of tools for pre-race preparation, on-stage emergency repairs and post-race maintenance. These tools will be deployed across demanding rally-raid environments — high heat, sand, dust and heavy mechanical loads — providing
More news about: DongCheng
Dec 07, 2025, 18:00 ET Anchorage Digital Integrates Middleware Provider BridgePort to Enhance Institutional Settlement Infrastructure
for off-exchange settlement by connecting exchanges, trading firms, and custodians which enable secure messaging for pre-order credit allocation and post-trade settlement facilitation. Founded by a team with decades of experience building fixed income and FX trading platforms for the world's largest traditional
More news about: BridgePort
Dec 07, 2025, 16:30 ET Lilly's Jaypirca (pirtobrutinib) met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica (ibrutinib)
president, Lilly Oncology. "These data build on additional results from the BRUIN development program and the recent FDA approval for pirtobrutinib in the post-covalent BTK inhibitor setting to reinforce the medicine's potential to deliver meaningful benefit for people living with CLL or SLL across various
More news about: Eli Lilly and Company
Dec 07, 2025, 12:01 ET Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec-drlb) Over Five Years
month 30 post-infusion.Favorable Safety Profile: No serious adverse events were related to treatment with HEMGENIX. HEMGENIX was generally well-tolerated, with a total of 100 treatment-related adverse events (TRAEs), most of which occurred in the first four months post-infusion. Only five
More news about: CSL
Dec 07, 2025, 04:21 ET CARsgen's CAR-T Product Zevor-Cel Included in China's Commercial Health Insurance Innovative Drug Catalogue
44.1 months and 43.2 months in CR/sCR patients, respectively. The median overall survival (mOS) was not reached. The patient survival rate at 60 months post-infusion was 76.9%.Dr. Huamao Wang, Co-founder and Chief Operating Officer of CARsgen, said: "We are very pleased to see zevor-cel included in
More news about: CARsgen Therapeutics
Dec 06, 2025, 15:40 ET Zenocutuzumab-zbco (BIZENGRI®) Shows Durable Efficacy in Patients with Treatment-Naïve NRG1+NSCLC: Updated eNRGy Trial Results Presented at IASLC-ASCO NACLC
Dec. 6, 2025 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx), a private, fully-integrated biotechnology company, announced new data from a post hoc analysis of the Phase 2 eNRGy trial (NCT02912949) evaluating zenocutuzumab in patients with treatment-naïve non-small cell lung cancer (NSCLC) harboring
More news about: Partner Therapeutics, Inc.
Dec 06, 2025, 09:30 ET Earlier use of CARVYKTI® demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma
mg/dL after infusion occurred in 94% (267/285) of patients treated. Fifty-six percent (161/285) of patients received intravenous immunoglobulin (IVIG) post CARVYKTI® for either an adverse reaction or prophylaxis.Monitor immunoglobulin levels after treatment with CARVYKTI® and
More news about: Johnson & Johnson
Dec 06, 2025, 08:30 ET Advances in Technology Help Improve Safety and Access to Blood Cancer Therapies
the long-term side effects of total body irradiation with a chemotherapy-based regimen.In the final study, researchers found that receiving a post-transplant cyclophosphamide-based graft-versus-host disease prevention strategy can overcome the negative effects previously associated with receiving
More news about: American Society of Hematology
Dec 06, 2025, 07:15 ET Studies Highlight Innovative Approaches to Improving Patient Care and Outcomes
been tested for iron deficiency. While this difference was not statistically significant, Dr. Godby said, it suggests that a reduction in the need for post-partum blood transfusions could be an additional benefit of treating iron deficiency during pregnancy.Dr. Godby noted that nearly all of the
More news about: American Society of Hematology
Dec 06, 2025, 07:00 ET Research Reveals Avenues for Informing and Improving Sickle Cell Care
median of five years post-transplant, were also largely positive. Most patients (86%) remained free from sickle cell disease symptoms with hemoglobin S levels at or below 50%, and most (74%) had no sickle cell disease-related complications reported at any time point post-transplant.Excluding infections,
More news about: American Society of Hematology